ProPhase Labs, Inc. Common Stock (DE) earnings per share and revenue
On 17 de nov. de 2025, PRPH reported earnings of -- USD per share (EPS) for Q3 25, -- the estimate of -0.11 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 5.80 milhão, with a --% difference.
Looking ahead to Q4 25, 3 analistas forecast an EPS of -0.12 USD, with revenue projected to reach 9.86 milhão USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Citius Pharmaceuticals Inc. Common
Report Date
26 de dez. de 2025 Para Q4 25
Estimativa
-$0.49
Real
-
Surpresa
-
FAQ
What were ProPhase Labs, Inc. Common Stock (DE)'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, ProPhase Labs, Inc. Common Stock (DE) reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to ProPhase Labs, Inc. Common Stock (DE)'s Q3 2025 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is ProPhase Labs, Inc. Common Stock (DE) expected to report next?
The next earning report is scheduled for 30 de mar. de 2026.
What are the forecasts for ProPhase Labs, Inc. Common Stock (DE)'s next earnings report?
Based on 3
analistas, ProPhase Labs, Inc. Common Stock (DE) is expected to report EPS of -$0.12 and revenue of $9.86M for Q4 2025.